← Back to Search

Transcatheter Aortic Valve Replacement System

TAVR for Bicuspid Aortic Valve Disease

N/A
Waitlist Available
Led By Basel Ramlawi, MD
Research Sponsored by Medtronic Cardiovascular
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Bicuspid aortic valve anatomy (all sub-types) confirmed by MDCT
Severe aortic stenosis defined by specific criteria for symptomatic and asymptomatic patients
Must not have
Multivessel coronary artery disease with a Syntax score >22 and/or unprotected left main coronary artery
Anatomical exclusion criteria including pre-existing prosthetic heart valve, severe mitral or tricuspid regurgitation, moderate or severe mitral stenosis, hypertrophic obstructive cardiomyopathy, prohibitive left ventricular outflow tract calcification, sinus of Valsalva diameter unsuitable for placement of the self-expanding bioprosthesis, aortic annulus diameter of <18 or >30 mm, significant ascending aortopathy, or ascending aorta diameter > 4.5 cm
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year and annually through 10 years
Awards & highlights

Summary

This trial tests the safety and effectiveness of the Medtronic TAVR system in patients with specific heart valve issues who are low risk for traditional surgery. The device replaces damaged heart valves through a small cut in the leg, avoiding open-heart surgery. This method has shown promise as an alternative to traditional surgery in patients with severe heart valve problems.

Who is the study for?
This trial is for patients with severe aortic stenosis and bicuspid aortic valve disease who are at low risk for surgical valve replacement. Participants must be over 60, have no major health issues like blood disorders or recent heart attacks, and not be pregnant or breastfeeding. They should agree to follow-up visits.
What is being tested?
The Medtronic TAVR system is being tested in this study to see if it's safe and effective for people with bicuspid aortic valves needing valve replacement but considered low-risk for traditional surgery.
What are the potential side effects?
Potential side effects may include reactions to materials used in the TAVR system, bleeding complications due to necessary anticoagulation therapy, infection risks, and possible impact on other heart valves.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My heart's aortic valve has two flaps and was confirmed by a CT scan.
Select...
I have been diagnosed with severe aortic stenosis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have severe heart artery blockage.
Select...
My heart does not have specific conditions that would prevent certain treatments.
Select...
I am under 60 years old.
Select...
I am not pregnant, breastfeeding, legally incompetent, or considered vulnerable.
Select...
I do not have blood disorders, ongoing infections, recent strokes, or artery disease in my neck.
Select...
I need emergency surgery.
Select...
I had a heart attack caused by unstable heart arteries within the last 30 days.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year and annually through 10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year and annually through 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Efficacy: Percent of Participants Who Meet All Device Success Criteria at 30 Days Post-procedure.
Safety: Percent of Participants With All-Cause Mortality or Disabling Stroke Rate at 30 Days Post-procedure.
Secondary study objectives
All Stroke (Disabling and Non-Disabling) Rate
All-Cause Mortality Rate
Change in Health-related Quality of Life (QoL) as Assessed by Kansas City Cardiomyopathy (KCCQ) Instrument at Baseline and 30 Days
+15 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Medtronic TAVR SystemsExperimental Treatment1 Intervention
Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Transcatheter Aortic Valve Replacement (TAVR) is a minimally invasive procedure used to treat severe aortic stenosis, including in patients with Bicuspid Aortic Valve (BAV). The mechanism of action involves inserting a catheter through the femoral artery to deliver and implant a new valve within the diseased aortic valve. This new valve takes over the function of regulating blood flow from the heart to the aorta, thereby improving cardiac output and reducing symptoms of aortic stenosis. For BAV patients, TAVR is particularly significant as it offers a less invasive alternative to open-heart surgery, reducing recovery time and associated risks, which is crucial for patients who may be at higher surgical risk due to the unique anatomy of BAV.
[Transcatheter aortic valve replacement : from a concept to a medical revolution].[Interventional catheter treatment of tricuspid valve regurgitation].Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee.

Find a Location

Who is running the clinical trial?

Medtronic CardiovascularLead Sponsor
75 Previous Clinical Trials
36,023 Total Patients Enrolled
Basel Ramlawi, MDPrincipal InvestigatorParamount Heart
1 Previous Clinical Trials
13 Total Patients Enrolled
Michael Reardon, MDStudy ChairThe Methodist Hospital Research Institute
7 Previous Clinical Trials
4,913 Total Patients Enrolled

Media Library

Medtronic TAVR Systems (Transcatheter Aortic Valve Replacement System) Clinical Trial Eligibility Overview. Trial Name: NCT03635424 — N/A
Bicuspid Aortic Valve Research Study Groups: Medtronic TAVR Systems
Bicuspid Aortic Valve Clinical Trial 2023: Medtronic TAVR Systems Highlights & Side Effects. Trial Name: NCT03635424 — N/A
Medtronic TAVR Systems (Transcatheter Aortic Valve Replacement System) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03635424 — N/A
~22 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top